Solt DB
@living.tech
Solt DB is a biotech equities research firm & public benefit company.
Memberships to investment research keep the finch 100% independent and fund our mission to build high-quality, open-source databases for the bioeconomy.
https://www.living.tech/
Memberships to investment research keep the finch 100% independent and fund our mission to build high-quality, open-source databases for the bioeconomy.
https://www.living.tech/
Americans are rightly pissed off at the broken American healthcare system. Earlier this year, we compiled the first-ever database of global blockbuster drug products.
Although Americans represent 4% of the world population, they generate 60% of global blockbuster sales.
Although Americans represent 4% of the world population, they generate 60% of global blockbuster sales.
World's Bestselling Drugs Addicted to Broken U.S. Healthcare System | Solt DB
The global drug development industry boasted 152 blockbuster drugs that generated combined revenue of $511 billion in 2023. Over 58% percent ($298 billion) was generated from patients in the United…
buff.ly
December 9, 2024 at 12:11 PM
Americans are rightly pissed off at the broken American healthcare system. Earlier this year, we compiled the first-ever database of global blockbuster drug products.
Although Americans represent 4% of the world population, they generate 60% of global blockbuster sales.
Although Americans represent 4% of the world population, they generate 60% of global blockbuster sales.
If you paid **ANY** U.S. income taxes from 2014 to 2023, then you had a higher tax rate than Pfizer.
The world's former-largest drug developer generated earnings before income taxes (EBIT) of $138 billion in that span. It spent $124 billion on dividends and share buybacks vs. $89.5 billion on R&D.
The world's former-largest drug developer generated earnings before income taxes (EBIT) of $138 billion in that span. It spent $124 billion on dividends and share buybacks vs. $89.5 billion on R&D.
November 20, 2024 at 12:11 PM
If you paid **ANY** U.S. income taxes from 2014 to 2023, then you had a higher tax rate than Pfizer.
The world's former-largest drug developer generated earnings before income taxes (EBIT) of $138 billion in that span. It spent $124 billion on dividends and share buybacks vs. $89.5 billion on R&D.
The world's former-largest drug developer generated earnings before income taxes (EBIT) of $138 billion in that span. It spent $124 billion on dividends and share buybacks vs. $89.5 billion on R&D.
Today, over 94% of all cotton, soybean, and corn grown in the U.S. harbors GE traits. That's up from 61%, 54%, and 25%, respectively, in 2000.
Rapid adoption was powered by the emergence of stacked traits, which combine weed and insect control into one seed.
Read more: https://buff.ly/4hPrtR3
Rapid adoption was powered by the emergence of stacked traits, which combine weed and insect control into one seed.
Read more: https://buff.ly/4hPrtR3
November 18, 2024 at 12:11 PM
Today, over 94% of all cotton, soybean, and corn grown in the U.S. harbors GE traits. That's up from 61%, 54%, and 25%, respectively, in 2000.
Rapid adoption was powered by the emergence of stacked traits, which combine weed and insect control into one seed.
Read more: https://buff.ly/4hPrtR3
Rapid adoption was powered by the emergence of stacked traits, which combine weed and insect control into one seed.
Read more: https://buff.ly/4hPrtR3
A supply shortage of Udenyca will impact Coherus BioSciences $CHRS in Q4, but it'll continue benefitting from solid commercial execution in 2025.
Q3 2024 vs. Q3 2023
➡️ Total oncology revenue +118%
➡️ Gross margin 70.7% vs. 56.1%
➡️ Operating loss $6.4m vs. $32.m
Q3 2024 vs. Q3 2023
➡️ Total oncology revenue +118%
➡️ Gross margin 70.7% vs. 56.1%
➡️ Operating loss $6.4m vs. $32.m
November 12, 2024 at 12:11 PM
A supply shortage of Udenyca will impact Coherus BioSciences $CHRS in Q4, but it'll continue benefitting from solid commercial execution in 2025.
Q3 2024 vs. Q3 2023
➡️ Total oncology revenue +118%
➡️ Gross margin 70.7% vs. 56.1%
➡️ Operating loss $6.4m vs. $32.m
Q3 2024 vs. Q3 2023
➡️ Total oncology revenue +118%
➡️ Gross margin 70.7% vs. 56.1%
➡️ Operating loss $6.4m vs. $32.m
Despite the recent stock plunge after Q3 results, Exact Sciences $EXAS has built a record amount of operating leverage.
The business generated $371 million in operating cash flow in the last 24 months.
It ended Sept with >$1 billion in cash for the first time since 2021.
The business generated $371 million in operating cash flow in the last 24 months.
It ended Sept with >$1 billion in cash for the first time since 2021.
November 11, 2024 at 12:11 PM
Despite the recent stock plunge after Q3 results, Exact Sciences $EXAS has built a record amount of operating leverage.
The business generated $371 million in operating cash flow in the last 24 months.
It ended Sept with >$1 billion in cash for the first time since 2021.
The business generated $371 million in operating cash flow in the last 24 months.
It ended Sept with >$1 billion in cash for the first time since 2021.
Immune checkpoint inhibitors have revolutionized cancer care, but PD-1 inhibitors generally have low response rates.
What if we could amplify their effects?
CCR8 is an emerging target that could enable valuable immuno-oncology (I-O) combos.
A flood of data is coming in 2025.
What if we could amplify their effects?
CCR8 is an emerging target that could enable valuable immuno-oncology (I-O) combos.
A flood of data is coming in 2025.
October 28, 2024 at 11:11 AM
Immune checkpoint inhibitors have revolutionized cancer care, but PD-1 inhibitors generally have low response rates.
What if we could amplify their effects?
CCR8 is an emerging target that could enable valuable immuno-oncology (I-O) combos.
A flood of data is coming in 2025.
What if we could amplify their effects?
CCR8 is an emerging target that could enable valuable immuno-oncology (I-O) combos.
A flood of data is coming in 2025.
Verve Therapeutics $VERV is taking another crack at PCSK9 silencing to reduce LDL-cholesterol.
CRISPR base editor VERVE-102 uses a refined LNP that should reduce side effects from VERVE-101. Base editing payload is the same.
Need LCL-C reductions of 50%-70% to be competitive.
CRISPR base editor VERVE-102 uses a refined LNP that should reduce side effects from VERVE-101. Base editing payload is the same.
Need LCL-C reductions of 50%-70% to be competitive.
October 23, 2024 at 11:11 AM
Verve Therapeutics $VERV is taking another crack at PCSK9 silencing to reduce LDL-cholesterol.
CRISPR base editor VERVE-102 uses a refined LNP that should reduce side effects from VERVE-101. Base editing payload is the same.
Need LCL-C reductions of 50%-70% to be competitive.
CRISPR base editor VERVE-102 uses a refined LNP that should reduce side effects from VERVE-101. Base editing payload is the same.
Need LCL-C reductions of 50%-70% to be competitive.
Inaugural @NucleateHQ Pittsburgh BioHack is this weekend!
10/25 ➡️ We're supplying @ZBioticsCompany for team formation & networking!
10/26 ➡️ Fireside chat with our founder @MaxxChatsko on building a biotech
10/27 ➡️ Maxx joins VCs Liam Krut & Zak Slayback as a Biotech Judge
10/25 ➡️ We're supplying @ZBioticsCompany for team formation & networking!
10/26 ➡️ Fireside chat with our founder @MaxxChatsko on building a biotech
10/27 ➡️ Maxx joins VCs Liam Krut & Zak Slayback as a Biotech Judge
October 21, 2024 at 6:11 AM
Inaugural @NucleateHQ Pittsburgh BioHack is this weekend!
10/25 ➡️ We're supplying @ZBioticsCompany for team formation & networking!
10/26 ➡️ Fireside chat with our founder @MaxxChatsko on building a biotech
10/27 ➡️ Maxx joins VCs Liam Krut & Zak Slayback as a Biotech Judge
10/25 ➡️ We're supplying @ZBioticsCompany for team formation & networking!
10/26 ➡️ Fireside chat with our founder @MaxxChatsko on building a biotech
10/27 ➡️ Maxx joins VCs Liam Krut & Zak Slayback as a Biotech Judge
Amgen $AMGN is conducting a 6,000 patient study to evaluate if olpasiran can reduce the risk of cardiovascular disease.
Designed by Arrowhead Pharma $ARWR , the RNAi drug candidate reduces apolipoprotein(a) regardless of cholesterol or LDL levels. Results expected late 2026.
Designed by Arrowhead Pharma $ARWR , the RNAi drug candidate reduces apolipoprotein(a) regardless of cholesterol or LDL levels. Results expected late 2026.
October 7, 2024 at 11:09 AM
Amgen $AMGN is conducting a 6,000 patient study to evaluate if olpasiran can reduce the risk of cardiovascular disease.
Designed by Arrowhead Pharma $ARWR , the RNAi drug candidate reduces apolipoprotein(a) regardless of cholesterol or LDL levels. Results expected late 2026.
Designed by Arrowhead Pharma $ARWR , the RNAi drug candidate reduces apolipoprotein(a) regardless of cholesterol or LDL levels. Results expected late 2026.
Opinion | The Synthetic Biology Ideology
This week's article explores why the storytelling and perception of synthetic biology companies often deviate from the realities of the underlying businesses.
#biotech #synbio #livingtech
www.living.tech/articles/opi...
This week's article explores why the storytelling and perception of synthetic biology companies often deviate from the realities of the underlying businesses.
#biotech #synbio #livingtech
www.living.tech/articles/opi...
Opinion | The Synthetic Biology Ideology | Solt DB
One quarter through the
www.living.tech
May 7, 2024 at 10:29 AM
Opinion | The Synthetic Biology Ideology
This week's article explores why the storytelling and perception of synthetic biology companies often deviate from the realities of the underlying businesses.
#biotech #synbio #livingtech
www.living.tech/articles/opi...
This week's article explores why the storytelling and perception of synthetic biology companies often deviate from the realities of the underlying businesses.
#biotech #synbio #livingtech
www.living.tech/articles/opi...
World's Bestselling Drugs Addicted to Broken U.S. Healthcare System
We compiled the world's 1st dataset of every blockbuster drug product. All 149.
It offers unrivaled insights into the drug industry and shows U.S. patients generate 60% of total sales.
www.living.tech/articles/wor...
We compiled the world's 1st dataset of every blockbuster drug product. All 149.
It offers unrivaled insights into the drug industry and shows U.S. patients generate 60% of total sales.
www.living.tech/articles/wor...
World's Bestselling Drugs Addicted to Broken U.S. Healthcare System | Solt DB
The global drug development industry boasted 149 blockbuster drugs that generated combined revenue of $507 billion in 2023. Over 58% percent ($296 billion) was generated from patients in the United St...
www.living.tech
March 26, 2024 at 2:59 PM
World's Bestselling Drugs Addicted to Broken U.S. Healthcare System
We compiled the world's 1st dataset of every blockbuster drug product. All 149.
It offers unrivaled insights into the drug industry and shows U.S. patients generate 60% of total sales.
www.living.tech/articles/wor...
We compiled the world's 1st dataset of every blockbuster drug product. All 149.
It offers unrivaled insights into the drug industry and shows U.S. patients generate 60% of total sales.
www.living.tech/articles/wor...
Will Supercomputers and AI Drive Biotech Breakthroughs?
We spoke with scientists at Lawrence Berkeley National Lab, the Pittsburgh Supercomputing Center, Recursion Pharmaceuticals, and Ginkgo Bioworks to go beyond the headlines and hype.
$RXRX $DNA
www.living.tech/articles/wil...
We spoke with scientists at Lawrence Berkeley National Lab, the Pittsburgh Supercomputing Center, Recursion Pharmaceuticals, and Ginkgo Bioworks to go beyond the headlines and hype.
$RXRX $DNA
www.living.tech/articles/wil...
Will Supercomputers and AI Drive Biotech Breakthroughs? | Solt DB
Artificial intelligence and machine learning help researchers to shape large datasets, but incredible computing power is still needed to muscle through biological data in a reasonable time. That's whe...
www.living.tech
December 15, 2023 at 3:53 PM
Will Supercomputers and AI Drive Biotech Breakthroughs?
We spoke with scientists at Lawrence Berkeley National Lab, the Pittsburgh Supercomputing Center, Recursion Pharmaceuticals, and Ginkgo Bioworks to go beyond the headlines and hype.
$RXRX $DNA
www.living.tech/articles/wil...
We spoke with scientists at Lawrence Berkeley National Lab, the Pittsburgh Supercomputing Center, Recursion Pharmaceuticals, and Ginkgo Bioworks to go beyond the headlines and hype.
$RXRX $DNA
www.living.tech/articles/wil...